Journal of vascular surgery. Venous and lymphatic disorders最新文献

{"title":"Evaluation of Factors Underlying Differences in Venous Thromboembolism Rates Between Black and White Patients.","authors":"Mary S Lin, Shalini Sahoo, Hilary Hayssen, Minerva Mayorga-Carlin, Brian Englum, Tariq Siddiqui, Phuong Nguyen, Yelena Yesha, John D Sorkin, Brajesh K Lal","doi":"10.1016/j.jvsv.2025.102270","DOIUrl":"https://doi.org/10.1016/j.jvsv.2025.102270","url":null,"abstract":"<p><strong>Objective: </strong>In the United States, the incidence of hospital-associated venous thromboembolism (VTE) has been found to be higher among blacks compared to whites. However, the reason for this difference is not well understood. Here we utilize a large, nationwide cohort to evaluate the clinical factors that may contribute to the difference in rates of VTE in black versus white patients.</p><p><strong>Methods: </strong>We analyzed consecutive first hospital admissions of black and white patients to all Veterans Affairs facilities from January 2016 to December 2021. We first compared VTE rates between white and black patients within 90-days of hospital admission, identified 11 potential confounders for the relationship between race and VTE, and used these to develop a series of adjusted logistic regression models predicting the development of VTE. Odds ratios (OR) obtained from these models were compared to examine the relationship between race, potential confounding variables, and VTE.</p><p><strong>Results: </strong>The study cohort consisted of 142,456 patients (mean age 54 years, 84.7% male), of whom 28.5% (N=40,632) were black and 71.5% (N=101,824) were white. 2.4% of the cohort developed a VTE within 90-days (N=3,455) and the rate of VTE was higher in black patients (2.7%) compared to white (2.3%, p<0.001). A total of 12 models were developed to examine individual confounders of the relationship between race and VTE. In all models, black race was associated with increased odds of VTE (OR 1.06-1.17). The strength of this association remained unchanged in the range of OR 1.13-1.16 after adjusting for major covariates including social deprivation index, blood type, and surgery type. When adjusting for hemoglobin, the OR for the association between black race and VTE was reduced. An inverse correlation was observed between black race and hemoglobin, with Pearson and Spearman correlation coefficients of -0.17 and -0.180, respectively.</p><p><strong>Conclusions: </strong>In this cohort of hospitalized patients, black race is a major risk factor for VTE, independent of social deprivation, blood type, and surgery. This effect may be modulated by hemoglobin, suggesting a potential clinical etiology underlying the trends observed between VTE and race.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102270"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Sirolimus Therapy for Patients with Complex Low-flow Vascular Malformations.","authors":"Rebecca Nisbet, Calver Pang, Nicholas Evans, Ahmed Belhadh, Mohamed Khalifa, Anthie Papadopoulou, Teji Randhawa, Jocelyn Brookes, Chung Sim Lim","doi":"10.1016/j.jvsv.2025.102261","DOIUrl":"https://doi.org/10.1016/j.jvsv.2025.102261","url":null,"abstract":"<p><p>The evidence on the efficacy and safety of sirolimus therapy in patients with low-flow vascular malformations (LFVM) has indicated its potential benefit in extensive and complicated lesions. This study aimed to assess the efficacy and safety of oral sirolimus therapy on complex LFVM patients when standard treatment alone was inadequate.</p><p><strong>Methods: </strong>This was a retrospective study of all adult patients with diagnosed LFVMs who were treated with oral sirolimus where standard therapy was inadequate in a single specialist centre from 1^st May 2016 until 30^th April 2023. Demographic and clinical data including patient reported responses, visual analogue scores for pain and adverse effects, and quality-of-life (QoL) scores (SF-36) were reviewed.</p><p><strong>Results: </strong>55 LFVM patients (14 with syndromic disease and 41 with non-syndromic) with a median age of 41 (range 23 to 72) years were included. 32 patients (58.2%) experienced some improvement whilst on sirolimus with a non-significant higher percentage of non-syndromic patients experiencing some improvements (p=0.6478). There was a non-significant improvement in the QoL scores for physical problems, energy/fatigue and pain. There was also a non-significant increase in anxiety and depression scores. There was a significant decrease in the lesion size (p=0.0004). Two patients reported a cessation of cellulitis episodes, and eight patients reported a partial or complete reduction in bleeding from their malformation or rectal bleeding. The most common side effects reported were mouth ulcers (54.5%), fatigue (29.1%), headache (25.5%), gastrointestinal problems (25.5%), rash (12.7%) and only five (9.1%) did not report any side effects. No significant difference was found between the side effects reported by syndromic and non-syndromic patients.</p><p><strong>Conclusion: </strong>Oral sirolimus therapy was clinically effective and safe in patients with complex LFVM when standard therapy alone was inadequate. Further studies with longer follow-up are needed to evaluate oral sirolimus therapy in LFVM patients.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102261"},"PeriodicalIF":2.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-year outcomes following endovascular treatment in patients with Post-Thrombotic Syndrome of the Lower Extremities.","authors":"Lin Zhang, Wei Song, Zheng Chen, Chuli Jiang, Yu Zhao, Fenghe Li","doi":"10.1016/j.jvsv.2025.102260","DOIUrl":"https://doi.org/10.1016/j.jvsv.2025.102260","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the safety and efficacy of endovascular treatment for post-thrombotic syndrome (PTS) in the lower extremities, and to identify risk factors contributing to in-stent restenosis.</p><p><strong>Methods: </strong>Patients with PTS who received endovascular treatment at our institution from May 2016 to April 2022 were included in this study. Clinical symptoms were systematically assessed utilizing the Villalta score, the CEAP (Clinical, Etiological, Anatomical, and Pathophysiological) classification, and the Venous Clinical Severity Score (VCSS). Primary and secondary patency rates were assessed by duplex ultrasound (DUS). Risk factors associated with in-stent restenosis were analyzed using univariate and multivariate Cox regression models. A repeated measures analysis of variance (ANOVA) was conducted to compare clinical symptom scores pre-and post-treatment.</p><p><strong>Results: </strong>A total of 115 patients were included in the study. The median follow-up duration was 48 months (range: 24-65 months). The primary patency rates at 3 months, 6 months, 1 year, 2 years, 3 years, and 4 years were 92.2% ± 2.5%, 88.7% ± 3.0%, 81.7% ± 3.6%, 73.9% ± 4.1%, 66.6% ± 4.5%, and 65.3% ± 4.6%, respectively. Stent restenosis was observed in 38 patients. At one year postoperatively, the VCSS exhibited a significant reduction of 7.0[ 95% Confidence Interval (CI): 6.0-8.0; P<0.001)] relative to preoperative levels. The Villalta score demonstrated a significant decrease of 11.4 (95% CI: 9.4-13.5; P<0.001) compared to preoperative levels. Cox regression analysis indicated that a CEAP classification of C5-C6 [hazard ratio (HR) = 2.24; 95% CI: 1.18-4.25; P = 0.014] was associated with stent restenosis.</p><p><strong>Conclusion: </strong>Endovascular treatment, with favorable long-term patency rates, is a safe and effective approach for managing PTS. CEAP classification of C5-C6 has been identified as a risk factor for stent restenosis.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102260"},"PeriodicalIF":2.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, Predictors, and Clinical Outcomes of Thrombus Propagation in Patients with Acute Isolated Calf Muscle Venous Thrombosis.","authors":"Yifei Bai, Xu Geng, Zhongzhi Jia, Tongqing Xue, Kai Wang","doi":"10.1016/j.jvsv.2025.102259","DOIUrl":"https://doi.org/10.1016/j.jvsv.2025.102259","url":null,"abstract":"<p><strong>Objective: </strong>The goal of this study was to evaluate the incidence, predictors, and clinical outcomes of thrombus propagation in patients with isolated calf muscle venous thrombosis (CMVT).</p><p><strong>Methods: </strong>This retrospective observational study included all consecutive hospitalized patients who were diagnosed with isolated CMVT between January 1, 2022, and August 1, 2024. Data on demographics, comorbidities, laboratory biomarkers, and management strategies were collected. The primary endpoint was the incidence of thrombus propagation (defined as either a previously localized thrombi within the muscular calf veins that was found to extend to the axis calf veins or proximal veins of the ipsilateral extremity, or as a thrombus that had clearly extended but remained confined to the muscular calf veins) during follow-up. Secondary endpoints included the incidence of venous thromboembolism (VTE) recurrence (defined as the formation of a new thrombus [ipsilateral or contralateral deep vein thrombosis or pulmonary embolism] confirmed by imaging during follow-up after complete resolution of the original CMVT), bleeding events, rehospitalization, and death.</p><p><strong>Results: </strong>Among the 459 patients included in this study, the incidence of CMVT propagation was 8.7% (n = 40). Independent predictors of thrombus propagation were immobilization (OR = 3.06[1.04-8.99], P = 0.042), history of VTE (OR = 4.31[1.42-13.05], P = 0.010), and elevated D-dimer level (OR = 1.06[1.02-1.09], P = 0.003). The mean time to propagation was 9.3 ± 5.2 days. VTE recurrence rates were 2.5% (n = 1) in patients with propagation and 1.7% (n = 7) in patients without propagation (P = 0.702). Major bleeding events occurred in 5.0% (n = 2) of patients with propagation and in 3.1% (n = 13) of patients without propagation (P = 0.519). During the follow-up period, no patients were rehospitalized or died due to VTE events.</p><p><strong>Conclusion: </strong>Thrombus propagation in patients with isolated CMVT is uncommon and generally not fatal. Predictors of CMVT propagation include immobilization, history of VTE, and elevated D-dimer level. These findings may help to identify patients with significant risk of CMVT propagation.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102259"},"PeriodicalIF":2.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital Arteriovenous Malformation of the Left Hip.","authors":"Hua Yi Zhang, Dong Zhe Chai","doi":"10.1016/j.jvsv.2025.102257","DOIUrl":"https://doi.org/10.1016/j.jvsv.2025.102257","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102257"},"PeriodicalIF":2.8,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"The Role of Venoactive Compounds in the Treatment of Chronic Venous Disease\".","authors":"Monika Lecomte Gloviczki, Stavros K Kakkos, Tomasz Urbanek, John Chuback, Andrew Nicolaides","doi":"10.1016/j.jvsv.2025.102258","DOIUrl":"https://doi.org/10.1016/j.jvsv.2025.102258","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic venous disease (CVD) is a major global health issue, affecting millions of people and contributing to significant morbidity and economic strain. The condition's pathophysiology is complex, involving both mechanical and biochemical processes that lead to venous reflux, obstruction, and chronic inflammation.</p><p><strong>Objective: </strong>This review will focus on the role of venoactive compounds (VACs), also known as venoactive drugs in Europe and other parts of the world, in managing CVD. The aim is to review the scientific evidence and to define the role of VACs within the comprehensive treatment algorithm for CVD, alongside established and well adopted interventional therapies and non-interventional therapies such as compression.</p><p><strong>Methods: </strong>The review of the scientific evidence was done on VACs mechanism of action and efficacy in alleviating CVD symptoms, reducing swelling or venous edema and improving healing of venous leg ulcers. Whenever available, systematic reviews, meta-analyses and randomized controlled trials were used. The quality of evidence assessment followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology with A = high, B = moderate, and C = low to very low quality.</p><p><strong>Results: </strong>Venoactive drugs or compounds share similar effects, such as sealing the endothelial barrier, enhancing lymphatic drainage, reducing edema, improving venous tone, inhibiting leukocyte adhesion to vein walls/valves and inflammatory mediator release, lowering blood viscosity, and promoting red blood cell flexibility. Scientific evidence on the VACs effectiveness on CVD symptoms (pain, cramps, heaviness) and swelling or edema have shown some variability. Micronized purified flavonoid fraction (MPFF) and ruscus extract combined with hesperidin methyl chalcone and ascorbic acid had the highest, mostly level A, quality of evidence. In venous leg ulcers MPFF, sulodexide and pentoxifylline were the most effective adjunctive treatment, with evidence level A.</p><p><strong>Conclusions: </strong>The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and non-interventional approaches like compression, to optimize patient outcomes and improve quality of life.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102258"},"PeriodicalIF":2.8,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ovarian vein embolization with N-butyl-2 cyanoacrylate for pelvic venous disorder: Analysis of 100 cases","authors":"Jose María Hipola MD ,&nbsp;Alberto Alonso MD, PhD ,&nbsp;Regina Cárdenas MD ,&nbsp;Eugenia Pillado MD ,&nbsp;Jose Ignacio Leal MD, PhD","doi":"10.1016/j.jvsv.2025.102256","DOIUrl":"10.1016/j.jvsv.2025.102256","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to evaluate the safety and efficacy of ovarian vein embolization using N-butyl-2 cyanoacrylate (NBCA) for treating pelvic venous disorder-associated chronic pelvic pain.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 100 patients who underwent ovarian vein embolization with NBCA at a single institution between February 2018 and June 2024. Pelvic venous insufficiency was confirmed by duplex ultrasound and abdominal computed tomography or magnetic resonance imaging, and NBCA was the sole embolic agent. Pain levels were assessed pre- and post-procedure using the Visual Analogue Scale (VAS) in three categories: pain on standing, dyspareunia, and menstrual pain. Follow-up included clinical evaluation and VAS scoring at 1 to 3 months and annually. Statistical analysis determined the significance of pain reduction.</div></div><div><h3>Results</h3><div>Technical success was achieved in all cases, with complete occlusion of the target veins. Clinical success was observed in most patients, with significant improvement in VAS scores across all categories (<em>P</em> &lt; .05). Due to symptom recurrence, four patients (4%) required reintervention during follow-up. No NBCA-related complications were reported.</div></div><div><h3>Conclusions</h3><div>In our study, ovarian vein embolization with NBCA appears to be a safe and effective treatment for pelvic venous disorder-associated chronic pelvic pain, providing significant pain relief. Additionally, it offers advantages over permanent metal implants such as the potential for gradual polymer degradation over time and avoiding interference in future imaging studies.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"13 5","pages":"Article 102256"},"PeriodicalIF":2.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-year follow-up of a randomized controlled trial comparing concomitant and staged treatment of varicose veins following mechanochemical ablation of the great saphenous vein.","authors":"Tasnuva Rahman, Katariina Noronen, Sari Vähäaho, Ivika Heinola, Maarit Venermo, Karoliina Halmesmäki","doi":"10.1016/j.jvsv.2025.102255","DOIUrl":"10.1016/j.jvsv.2025.102255","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Mechanochemical ablation is a feasible endovenous nonthermal, nontumescent treatment method for saphenous vein insufficiency.&lt;sup&gt;1,2,3&lt;/sup&gt; Nevertheless, the ideal approach to managing varicose veins following intervention of the saphenous trunk remains ambiguous.&lt;sup&gt;1&lt;/sup&gt; Treatment of varicose veins can be administered either simultaneously or in a staged manner.&lt;sup&gt;1&lt;/sup&gt; The aim of this 3-year follow-up study was to present the midterm outcomes of a randomized controlled trial, comparing concomitant and staged treatment of tributaries.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Venous outpatient clinic patients with unilateral Clinical, Etiological, Anatomical, Pathophysiological (CEAP) C2-4 venous disease were enrolled in a randomized controlled trial during 2016 to 2017 at Helsinki University Hospital. After eligibility assessment of 1149 patients, 85 met the inclusion criteria: age of 20 to 70 years, ultrasound-verified refluxing above-knee great saphenous vein with a diameter of 5 to 10 mm, written consent from patients, and not having deep venous reflux, peripheral artery disease, pregnancy, lymphoedema, body mass index &gt;40 kg/m&lt;sup&gt;2&lt;/sup&gt;, allergy to the sclerosant, a history of deep vein thrombosis, or any form of coagulopathy. Participants were randomized, in a 1:1 ratio, to receive either staged tributary treatment with foam sclerotherapy at 3 months, if required (Group 1), or concomitant phlebectomies (Group 2), adjunct to mechanochemical ablation of the great saphenous trunk. All patients were invited to attend a 3-year follow-up, during which the initially treated leg was assessed with duplex ultrasound. The primary outcome was reintervention rate during follow-up. Secondary outcomes comprised presence of above-knee great saphenous vein reflux, patient satisfaction, status of the great saphenous vein, number of varicose veins, and symptoms at follow-up.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;During follow-up, 11.4% (n = 5/44) (95% confidence interval [CI], 0.02-0.21) in Group 1 and 4.9% (n = 2/41) (95% CI, -0.02 to 0.11) in Group 2 was in need of additional treatment (Group 1 vs Group 2, odds ratio [OR], 2.5; 95% CI, 0.46-13.67; P = .435). The treatment groups did not elicit statistically significant variances in above-knee great saphenous vein reflux (P = .603), disease-specific and health-related quality of life (P = .238 and P = .255, respectively), status of the great saphenous vein (P = .112), or symptoms. However, noninferiority analysis suggests the staged approach to be inferior to the concomitant approach. Furthermore, Group 1 exhibited more varicosities at 3 years compared with Group 2, but this did not cause differences in the extent of symptoms or overall patient satisfaction.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Staged treatment of tributaries in C2-4 venous disease provides acceptable midterm outcomes compared with simultaneous treatment. However, its potential inferiority should be taken into cons","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102255"},"PeriodicalIF":2.8,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An artificial intelligence interpretable tool to predict risk of deep vein thrombosis after endovenous thermal ablation.","authors":"Azadeh Tabari, Yu Ma, Jesus Alfonso, Anthony Gebran, Haytham Kaafarani, Dimitris Bertsimas, Dania Daye","doi":"10.1016/j.jvsv.2025.102253","DOIUrl":"10.1016/j.jvsv.2025.102253","url":null,"abstract":"<p><strong>Objective: </strong>Endovenous thermal ablation (EVTA) stands as one of the primary treatments for superficial venous insufficiency. Concern exists about the potential for thromboembolic complications following this procedure. Although rare, those complications can be severe, necessitating early identification of patients prone to increased thrombotic risks. This study aims to leverage artificial intelligence-based algorithms to forecast patients' likelihood of developing deep vein thrombosis (DVT) within 30 days following EVTA.</p><p><strong>Methods: </strong>From 2007 to 2017, all patients who underwent EVTA were identified using the American College of Surgeons National Surgical Quality Improvement Program database. We developed and validated four machine learning models using demographics, comorbidities, and laboratory values to predict the risk of postoperative DVT: Classification and Regression Trees (CART), Optimal Classification Trees (OCT), Random Forests, and Extreme Gradient Boosting (XGBoost). The models were trained using all the available variables. SHapley Additive exPlanations analysis was adopted to interpret model outcomes and offer medical insights into feature importance and interactions.</p><p><strong>Results: </strong>A total of 21,549 patients were included (mean age, 54 ± 14 years; 67% female). In this cohort, 1.59% developed DVT. The XGBoost model had good discriminative power for predicting DVT risk with area under the curve of 0.711 in the hold-out test set for the all-variable model. Stratification of the test set by age, body mass index, preoperative white blood cell count, and platelet count shows that the model performs equally well across these groups.</p><p><strong>Conclusions: </strong>We developed and validated an interpretable model that enables physicians to predict which patients with superficial venous insufficiency has higher risk of developing DVT within 30 days following EVTA.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102253"},"PeriodicalIF":2.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traumatic iliac arteriovenous fistula with giant venous aneurysm following lumbar spine surgery","authors":"Aoi Ogawa BA,&nbsp;Dylan Goto MD,&nbsp;Elna Masuda MD","doi":"10.1016/j.jvsv.2025.102254","DOIUrl":"10.1016/j.jvsv.2025.102254","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"13 5","pages":"Article 102254"},"PeriodicalIF":2.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}